KALA - Kala Pharmaceuticals GAAP EPS of -$0.38 revenue of $2.1M
- Kala Pharmaceuticals press release ( NASDAQ: KALA ): Q2 GAAP EPS of -$0.38.
- Revenue of $2.1M (-31.1% Y/Y).
- As of June 30, 2022, Kala had cash, cash equivalents and short-term investments of $44.6M, compared to $92.1M of cash and cash equivalents as of December 31, 2021.
- Based on its current plans, Kala anticipates that its cash resources as of June 30, 2022, together with the net proceeds from the Alcon transaction and associated reduction in operating expenses, will enable it to fund its operations into the second quarter of 2024.
For further details see:
Kala Pharmaceuticals GAAP EPS of -$0.38, revenue of $2.1M